Choi et al. [89] reported the highest LC3B expression in triple-negative breast cancers, and Zhao et al. [49] observed the association of high LC3B expression with poor overall survival and disease progression in patients with this cancer subtype. Here, MAP1LC3B is linked to triple-negative breast carcinoma.